ALX Oncology Stock Forecast, Price & News

-1.29 (-2.24 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume398,658 shs
Average Volume226,150 shs
Market Capitalization$2.27 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALXO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

ALX Oncology logo

About ALX Oncology

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.21 out of 5 stars

Medical Sector

132nd out of 2,218 stocks

Pharmaceutical Preparations Industry

60th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 4.2Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ALX Oncology (NASDAQ:ALXO) Frequently Asked Questions

Is ALX Oncology a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALX Oncology stock.
View analyst ratings for ALX Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than ALX Oncology?

Wall Street analysts have given ALX Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ALX Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ALX Oncology's next earnings date?

ALX Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 26th 2021.
View our earnings forecast for ALX Oncology

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) posted its earnings results on Sunday, May, 16th. The company reported ($0.35) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.06.
View ALX Oncology's earnings history

What price target have analysts set for ALXO?

7 analysts have issued 1-year price objectives for ALX Oncology's stock. Their forecasts range from $50.00 to $103.00. On average, they anticipate ALX Oncology's share price to reach $90.67 in the next year. This suggests a possible upside of 60.9% from the stock's current price.
View analysts' price targets for ALX Oncology
or view top-rated stocks among Wall Street analysts.

Who are ALX Oncology's key executives?

ALX Oncology's management team includes the following people:
  • Dr. Corey S. Goodman, Independent Exec. Chairman (Age 69, Pay $38.5k)
  • Dr. Jaume Pons Ph.D., Pres, CEO & Director (Age 55, Pay $1.28M)
  • Mr. Peter S. Garcia, Chief Financial Officer (Age 59, Pay $817.65k)
  • Dr. Sophia Randolph M.D., Ph.D., Chief Medical Officer & Director (Age 53, Pay $938.5k) (LinkedIn Profile)
  • Dr. Michael Chang Ph.D., VP of Operations
  • Ms. Shelly Pinto, VP of Fin. & Chief Accounting Officer (Age 45)
  • Dr. Michael Warner J.D., Ph.D., Gen. Counsel
  • Ms. Jeanne Y. Jew, Chief Bus. Officer (Age 57)

Who are some of ALX Oncology's key competitors?

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and Axon Enterprise (AAXN).

When did ALX Oncology IPO?

(ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at a price of $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager.

What is ALX Oncology's stock symbol?

ALX Oncology trades on the NASDAQ under the ticker symbol "ALXO."

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Lindbrook Capital LLC (0.00%). Company insiders that own ALX Oncology stock include G Walmsley Graham, Jaume Pons and Sophia Randolph.
View institutional ownership trends for ALX Oncology

Which institutional investors are buying ALX Oncology stock?

ALXO stock was acquired by a variety of institutional investors in the last quarter, including Lindbrook Capital LLC.
View insider buying and selling activity for ALX Oncology
or or view top insider-buying stocks.

How do I buy shares of ALX Oncology?

Shares of ALXO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ALX Oncology's stock price today?

One share of ALXO stock can currently be purchased for approximately $56.36.

How much money does ALX Oncology make?

ALX Oncology has a market capitalization of $2.27 billion and generates $1.18 million in revenue each year. The company earns $-45,740,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis.

How many employees does ALX Oncology have?

ALX Oncology employs 24 workers across the globe.

What is ALX Oncology's official website?

The official website for ALX Oncology is

Where are ALX Oncology's headquarters?

ALX Oncology is headquartered at 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010.

How can I contact ALX Oncology?

ALX Oncology's mailing address is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. The company can be reached via phone at 650-466-7125 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.